US Biologics Safety Testing Market (2026-2031)
The US Biologics Safety Testing Market was valued at $1154.5 Million in 2026 and projected to reach to $2071.6 Million by 2031, representing a compound annual growth rate of 12.4%. The US biologics safety testing market is poised for sustained expansion through 2031, driven by accelerating development of complex biologics including monoclonal antibodies, cell and gene therapies, and biosimilars.
US Biologics Safety Testing Market Trends and Insights
- This expansion reflects the US regulatory environment's stringent requirements for biopharmaceutical development and the rising complexity of monoclonal antibodies, cell therapies, and gene therapies entering the US market.
- The US dominates North America's biologics safety testing landscape, driven by substantial R&D investments from pharmaceutical companies and contract research organizations (CROs) operating within the country. The US market's 12.4% compound annual growth rate significantly outpaces global trends, underscoring the country's position as a critical hub for biologics innovation and safety assessment.
- Throughout the 2026–2031 forecast period, the US will continue to benefit from FDA regulatory pressures, increased outsourcing to specialized testing providers, and growing demand for advanced safety testing methodologies.
- The US market's expansion is further supported by the proliferation of biosimilars and the need for comprehensive safety profiling across diverse biologic modalities..
Key Market Statistics
- CAGR (2026-2031) 12.4% CAGR
- Market Size, 2026 ~USD 1154.5 Million
- Forecast, 2031 ~USD 2071.6 Million
- Country US
US Biologics Safety Testing Market Overview
Market Valuation Growth :
The US biologics safety testing market is valued at $1,154.5 million in 2026 and is projected to reach $2,071.6 million by 2031, representing a robust 12.4% CAGR driven by increased biopharmaceutical development and regulatory compliance demands.
Regulatory Stringency :
The US FDA's stringent requirements for biopharmaceutical development necessitate comprehensive safety testing protocols, positioning the US as a critical market for advanced testing solutions and compliance services.
Advanced Therapy Complexity :
Rising complexity of monoclonal antibodies, cell therapies, and gene therapies entering the US market demands sophisticated safety testing methodologies, creating sustained demand for specialized testing services and expertise.
Market Dominance :
The US maintains dominant market position in the global biologics safety testing landscape, reflecting its leadership in biopharmaceutical innovation, regulatory standards, and investment in advanced therapeutic development.
US Biologics Safety Testing Market Dynamics
- Stringent FDA regulations and post-market surveillance requirements continue to elevate safety testing standards, compelling biopharmaceutical companies to invest in comprehensive testing infrastructure.
- The market benefits from increasing R&D spending, growing clinical trial activities, and heightened focus on patient safety across the US pharmaceutical sector. Key growth catalysts include the proliferation of personalized medicine approaches, expansion of immunotherapy pipelines, and regulatory emphasis on comprehensive characterization of biological products.
- Contract research organizations (CROs) and specialized testing laboratories are expanding capacity to meet demand.
- The US market's maturity and regulatory sophistication position it as a benchmark for global safety testing standards, ensuring continued investment and innovation in testing methodologies and technologies..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- The US biologics safety testing market will nearly double from $1,154.5M (2026) to $2,071.6M (2031), reflecting strong demand for regulatory compliance.
- The US market's 12.4% CAGR outpaces the global average, positioning the US as the fastest-growing major market for biologics safety testing.
- FDA regulatory requirements and the complexity of advanced biologic modalities drive sustained investment in safety testing infrastructure across the US.
- The US market benefits from a mature CRO ecosystem and significant pharmaceutical R&D spending, supporting continued expansion through 2031.
Biologics Safety Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | STERILITY TESTING SERVICES (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 11.6% from 2026 to 2031 |
| Largest Segment | SERVICES (Offering) |
| Market Size Base Year (Billions) | ~USD 5.58 (2026) |
| Revenue Forecast (Billions) | ~USD 9.66 (2031) |
| Segments Covered | Offering, Type, Product & Service, Test Type, Application, End User |
US Biologics Safety Testing Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Bioburden Testing Services
- Endotoxin Testing Services
- Mycoplasma Testing Services
- Other Biologics Safety Testing Services
- Other Bst Services
- Sterility Testing Services
- Virus Safety Testing Services
By Product & Service
- Consumables
- Instruments
- Services
By Test Type
- Bioburden Tests
- Endotoxin Tests
- Mycoplasma Tests
- Other Biologics Safety Tests
- Residual Host Cell Proteins & Dna Detection Tests
- Sterility Tests
- Virus Safety Tests
By Application
- Blood & Blood Products Development And Manufacturing
- Cellular & Gene Therapy Products Development And Manufacturing
- Monoclonal Antibodies Development And Manufacturing
- Other Applications
- Vaccines Development And Manufacturing
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Pharmaceutical & Biotechnology Companies
Target Audience
- Biopharmaceutical Companies : US-based and international biopharma firms developing monoclonal antibodies, cell therapies, and gene therapies require detailed market intelligence on safety testing requirements, regulatory pathways, and CRO capabilities to optimize development timelines and ensure FDA compliance.
- Contract Research Organizations (CROs) : CROs and specialized testing laboratories need US market data to assess growth opportunities, benchmark service offerings, identify capacity expansion requirements, and develop strategic partnerships with biopharmaceutical clients in the high-value US market.
- Regulatory & Compliance Professionals : Regulatory affairs teams and compliance officers require comprehensive understanding of US FDA requirements, testing standards, and market trends to develop robust safety assessment strategies and maintain competitive advantage in biopharmaceutical development.
- Investment & Strategy Teams : Private equity firms, venture capital investors, and corporate strategy teams evaluating opportunities in the biologics testing sector need US market sizing, growth projections, and competitive dynamics to inform investment decisions and portfolio strategy.
- Testing Technology & Equipment Providers : Manufacturers of testing equipment, analytical instruments, and laboratory technologies require US market insights to identify customer segments, assess demand for advanced testing methodologies, and develop solutions aligned with evolving biopharmaceutical safety requirements.
Key Companies in the US Biologics Safety Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Drug Product Services (finished dosage manufacturing, packaging, lifecycle management),Pharmaceutical Development Services (formulation, clinical trial supply),Drug Substance Services (API and biologics substance), |
| SIGMA-ALDRICH CORPORATION | United States | Private Company | Chemicals and Biochemicals Catalog,Cell Culture, Media, and Critical Raw Materials,Filtration, Labware, and Water Purification, |
| WUXI PHARMATECH (CAYMAN) INC | China | Private Company | Chemistry drug CRDMO services,Biology discovery and preclinical testing,Clinical research services, |
| FLUOR CORPORATION | United States | Public Company | Energy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining, infrastructure, staffing, maintenance),Mission Solutions (government, nuclear remediation, security, logistics, O&M), |
| AZELIS HOLDINGS SA | Belgium | Private Company | Coatings, Plastics & Advanced Materials Specialties,Food & Nutrition Ingredients,Personal Care & Home Care Ingredients, |
| CATALENT, INC. | United States | Private Company | Biologics (proteins, cell and gene, parenteral, large-molecule analytics),Pharma and Consumer Health – softgels and advanced oral dose (incl. Zydis),Pharma and Consumer Health – other oral, nasal, inhaled, topical, |
PATHEON INC
Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and biotechnology services sector.
SIGMA-ALDRICH CORPORATION
Sigma-Aldrich Corporation is a United States-based private company founded in 1951 with 9,800 employees specializing in life science and chemical products.
WUXI PHARMATECH (CAYMAN) INC
Wuxi Pharmatech (Cayman) Inc. is a China-based private company founded in 2000 with 8,837 employees providing pharmaceutical research and development services.
FLUOR CORPORATION
Fluor Corporation is a United States-based public company founded in 1912 with 22,995 employees operating in engineering, procurement, and construction services.
AZELIS HOLDINGS SA
Azelis Holdings SA is a Belgium-based private company founded in 2001 with 1,325 employees specializing in specialty chemicals and ingredients.
CATALENT, INC.
Catalent, Inc. is a United States-based private company founded in 1933 with 16,900 employees offering pharmaceutical development and manufacturing services.
Reasons to Buy this Report
- Market Size & Growth Validation : Quantified US market data with precise valuations ($1,154.5M in 2026 to $2,071.6M in 2031) and 12.4% CAGR enables accurate financial forecasting, investment planning, and resource allocation for market participants.
- Regulatory Landscape Intelligence : Detailed insights into FDA stringency and US regulatory requirements provide critical context for compliance strategy development, helping organizations align testing protocols with evolving regulatory standards and avoid costly non-compliance.
- Competitive Positioning Strategy : US-specific market analysis identifies growth drivers in monoclonal antibodies, cell therapies, and gene therapies, enabling companies to benchmark capabilities, identify service gaps, and develop targeted competitive strategies for the dominant US market.
- Investment & Expansion Planning : Comprehensive US market outlook supports capital allocation decisions, facility expansion planning, and M&A strategy by quantifying market opportunity, growth trajectory, and emerging demand segments specific to the American biopharmaceutical ecosystem.
- Customer & Partnership Development : Detailed understanding of US market dynamics, target customer segments, and growth catalysts enables CROs, testing labs, and service providers to identify high-value customer opportunities and develop tailored solutions for the US biopharmaceutical sector.
Frequently asked questions
What is the current size of the US biologics safety testing market?
The US biologics safety testing market is estimated at $1,154.5 million in 2026 and is projected to reach $2,071.6 million by 2031.
What is the growth rate of the US biologics safety testing market?
The US market is expected to grow at a compound annual growth rate (CAGR) of 12.4% from 2026 to 2031.
Why is the US biologics safety testing market growing faster than the global average?
The US market's 12.4% CAGR exceeds the global 11.6% CAGR due to stringent FDA regulations, high pharmaceutical R&D investment, and the prevalence of complex biologic therapies requiring comprehensive safety assessment.
What factors are driving growth in the US biologics safety testing market?
Key drivers include FDA regulatory compliance requirements, increasing complexity of monoclonal antibodies and cell therapies, biosimilar development, and growing outsourcing to specialized CROs in the US.
How much will the US biologics safety testing market grow by 2031?
The US market is projected to grow by $917.1 million from 2026 to 2031, representing an 79.4% increase over the five-year forecast period.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the biologics safety testing market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the US Food and Drug Administration (FDA), World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), News Articles, Press Releases. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global biologics safety testing market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the biologics safety testing market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The biological safety testing market comprises the products and services used to assess the safety, purity, potency, and quality of biologically derived products across their development, manufacturing, and release stages.
Key Stakeholders
- Biologics safety testing products and services companies
- National and regional research boards and organizations
- Research & development companies
- Clinical research organizations (CROs)
- Biotechnology companies
- Research laboratories & academic institutes
- Market research & consulting firms
- Regulatory bodies
Report Objectives
- To define, describe, and forecast the biologics safety testing market by offering, test type, product application, service application, product end user, service end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biologics safety testing market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe biologics safety testing market, by country
- Further breakdown of the Rest of Asia Pacific biologics safety testing market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Get the Full Biologics Safety Testing Market Report
Full forecast, segment splits, and company analysis for all Biologics Safety Testing Market.
- Canada Biologics Safety Testing Market
- UK Biologics Safety Testing Market
- Germany Biologics Safety Testing Market
- France Biologics Safety Testing Market
- Italy Biologics Safety Testing Market
- Spain Biologics Safety Testing Market
- China Biologics Safety Testing Market
- Japan Biologics Safety Testing Market
- India Biologics Safety Testing Market
- South Korea Biologics Safety Testing Market
- Australia Biologics Safety Testing Market
- Brazil Biologics Safety Testing Market
- Mexico Biologics Safety Testing Market
- Saudi Arabia Biologics Safety Testing Market
- UAE Biologics Safety Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report